Reteplase in treatment of acute ST elevation myocardial infarction: clinical study of 245 cases

Abstract

Objective To investigate the clinical efficacy and safety of Reteplase in the treatment of acute ST segment elevation myocardial infarction(STEMI) with different onset time. Methods The clinical data of 245 patients with STEMI who received Reteplase thrombolytic therapy and the onset of the disease within 6h in the People's Hospital of Linyi County were retrospectively analyzed.According to the time of onset of the disease, the patients were divided into two groups.The onset of the disease in group 1 was less than 3h, that in group 2 was 3-6h.The recanalization rate, recanalization time, the incidence rate of bleeding and mortality were compared between the two groups. Results The recanalization rate of group 1 (94.63%) was higher than that of group 2(92.70%), but the difference was not statistically significant(χ2=3.80, P 0.05). The mortality of group 1 was 3.36%, which of group 2 was 3.12%, the difference was not statistically significant (P>0.05). Conclusion Reteplase for the STEMI patients with onset of the disease within 3h, the recanalization time is shorter than STEMI patients with onset of the disease 3-6h.The rate of recanalization is higher, and there is no significant difference in the rate of bleeding and in-hospital mortality. Key words: Myocardial infarction; Tissue plasminogen activator; Thrombolytic therapy